One-year experience in patients treated with auranofin following completion of a parallel, controlled trial comparing auranofin, gold sodium thiomalate, and placebo.
Following a 21-week double-blind trial that compared the effects of treatment with auranofin (AUR), gold sodium thiomalate, and placebo in 193 patients, 147 patients entered a 1-year, open-label study of treatment with AUR (6 mg/day). Results of this open-label study suggest that AUR has a long-term use profile similar to that of other slow-acting antirheumatic drugs. AUR appears to be capable of sustaining an initial response to gold sodium thiomalate. The withdrawal rate remains relatively high: Nearly half of the study patients had discontinued AUR by the end of 1 year.
D000293:Adolescent; D000328:Adult; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000503:physiopathology; D001310:Auranofin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005500:Follow-Up Studies; D006052:Gold Sodium Thiomalate / Q000627:therapeutic use; D006801:Humans; D007596:Joints / Q000503:physiopathology; D010146:Pain; D010352:Patient Dropouts
D006052:Gold Sodium Thiomalate; D001310:Auranofin